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Abstract
Early identification of fetal alcohol spectrum disorders (FASDs) is important for providing 
services and preventing secondary disabilities. Recent studies indicate that many FASDs are 
undiagnosed, partly because there is a need to improve detection of prenatal alcohol exposure 
(PAE). The aims of this review are to characterize existing practices for assessing PAE in 
pediatric care, identify the most efficient, promising methods of detecting PAE, and recognize the 
knowledge and practice gaps. This review indicates that maternal self-reports remain the most 
common method utilized in routine clinical practice and highlights promising methods of PAE 
identification, including a single binge drinking question. The review yields few studies describing 
existing strategies to assess PAE in pediatric practice and identifies knowledge gaps that need to 
be addressed for improving recognition of FASDs in pediatric practice.
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Introduction
Accurate identification of FASDs is important for providing services and preventing 
disorders secondary to FASDs. Research indicates that early diagnosis of a child affected by 
prenatal alcohol exposure (PAE) is associated with better health and life outcomes [1]. 
However, FASDs remain largely underdiagnosed. The Centers for Disease Control and 
Prevention (CDC) acknowledged that FASD surveillance is inadequate and that the number 
of children adversely affected by in-utero exposure to alcohol is underestimated [2••]. The 
CDC Fetal Alcohol Syndrome (FAS) Surveillance Network (FASSNet) II [2••] utilized 
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medical records in several states and identified 0.3 children with FAS per 1,000 children 
aged 7-9 years. This figure is significantly lower than the prevalence reported by active case 
ascertainment studies, in which an expert evaluates children in person; these studies 
estimated 2-to-7 children affected by FAS and 20-to-50 affected by FASDs per 1,000 
children in the U.S. and Western Europe, approximately 2% to 5% of the population [3••]. 
Another study reported the prevalence of FASDs among first grade students in a 
representative Midwestern US community as 6-9 per 1,000 children, Partial Fetal Alcohol 
Syndrome (PFAS) as 11-17 per 1,000 children, and the overall rate of FASDs as 24-48 per 
1,000 children, or 2.4% to 4.8% [4]. A recent study reported that 86.5% of foster and 
adopted youth with FASDs were undiagnosed (80.1%) or were diagnosed incorrectly within 
the FASD spectrum (6.4%) prior to a comprehensive evaluation in a specialized clinic [5••].
Data about women's alcohol consumption indicate that more children may be affected by 
PAE and be at high risk for FASDs. Per the CDC Behavioral Risk Factor Surveillance 
System (BRFSS), 7.6% of pregnant women report consuming alcohol in the past 30 days; 
1.4% report binge drinking, defined as consuming four or more alcoholic drinks (standard-
sized drink equivalents are included in Figure 1) per occasion during the past 30 days [6•]. 
According to BRFSS data, among non-pregnant women of childbearing age, the prevalence 
of any alcohol use in the last 30 days is 51.5% and the prevalence of binge drinking is 15%, 
which is higher among young women who are more likely to have children, including 
women aged 18–24 years (24.2%) and 25–34 years (19.9%) [6]. Moreover, about half of 
pregnancies in U.S. are unintended, and a woman may not know she is pregnant until 4-6 
weeks of gestation [7]. Given that women often continue to consume alcohol at pre-
pregnancy levels until they become aware of their pregnancy [8], there is a high likelihood 
of PAE before pregnancy recognition, with binge drinking of particular concern because it 
causes high blood alcohol concentration. Therefore, many pregnancies may be affected by 
PAE early on, placing children at risk for FASDs.
Some cases might not be diagnosed because of the syndromic nature of FASDs, the lack of 
pathognomonic features, and the negative perceptions associated with alcohol use during 
pregnancy. The physical features of FAS are often subtle, and the hallmark facial features 
(smooth philtrum, thin vermillion, small palpebral fissures) are not always fully apparent at 
birth [9], are difficult to accurately assess without precise measurement [10], and sometimes 
become less apparent with age. Fox et al. [2••] noted that healthcare providers inadequately 
recognize facial features of FAS and often fail to document the features in the patient's 
records with over half of health providers in this study reporting that they received no 
training in recognizing FASDs. Several genetic syndromes may present with similar features 
and require differential diagnosis. Furthermore, physical features may not be present in 
Partial FAS (PFAS) and in non-dysmorphic FASDs, including Neurobehavioral Disorder 
Associated with Prenatal Alcohol Exposure (ND-PAE), a new diagnostic category 
introduced in the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM 
5) [11]. The ND-PAE was established to recognize individuals who do not meet full criteria 
for FAS, but have impairments in neurocognitive, self-regulatory, and adaptive functioning, 
and known PAE [11]. The introduction of ND-PAE in the DSM 5 emphasizes the 
importance of identifying PAE. Unlike FAS, which can be diagnosed without information 
about PAE history, diagnosing ND-PAE and other non-dysmorphic FASDs requires a 
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confirmed history of more than minimal prenatal exposure. The “minimal” exposure is 
defined as 1-to-13 drinks/month and no more than 2 drinks per one occasion [11]. Therefore, 
accurate detection of PAE is necessary to improve identification of children with FASDs 
and provide services to prevent adverse outcomes.
This paper focuses on detection of PAE to improve the identification of FASDs in pediatric 
practice. The primary aims of this article are to 1) characterize existing practice and 
strategies to assess PAE in pediatric care, 2) identify the most efficient, promising methods 
of detecting PAE, and 3) recognize the knowledge and practice gaps that must be addressed 
in order to improve recognition of FASDs in pediatric practice.
Review of PAE screening practices and strategies among pediatric and 
other clinicians
A systematic literature search was conducted for studies reporting on PAE screening 
practices among pediatric clinicians, related guidelines, and barriers to alcohol screening and 
FASD identification. Because an initial search identified few studies focusing on screening 
among pediatric clinicians, the search was expanded to include obstetricians, family 
physicians, and other healthcare providers who provided salient information about PAE 
screening processes, knowledge base, or competence. Since this review focused on PAE 
screening among pediatric clinicians, data about other physicians’ practices were only 
included for comparison purposes. No comprehensive review of alcohol screening by other 
health care providers was conducted. Studies were excluded if they focused on an overview 
of FASDs/FAS or its diagnostic process, or if they did not address eliciting a maternal self-
report of PAE.
We searched the Ovid Medline and PubMed search engines using a date range of <1946 to 
February Week 2 2015> for “alcohol and pregnancy and screen” AND “physician's practice 
patterns/or pediatrics/ or pediatrician.” Adding “self-report” to this search or substituting it 
for “screen” yielded the same or fewer results. We also performed a search to find articles 
on the topic of “Physician awareness and screening for fetal alcohol syndrome,” and 
conducted a general GoogleScholar search on these terms. Our overall search yielded 27 
articles. After excluding articles based on the above criteria and those unavailable in full 
text, two articles were identified as relevant to our primary question of current pediatric 
screening practices and strategies to identify alcohol consumption during pregnancy. Six 
additional articles addressed our question in other provider populations and/or assessed 
pediatric attitudes regarding screening for PAE. An additional search was conducted to 
examine reports about promising methods of identification of alcohol consumption during 
pregnancy and barriers and challenges to PAE identification.
Professional guidelines on detecting PAE
The U.S. Surgeon General (2005) issued a statement that health professionals should inquire 
routinely about alcohol consumption by women of childbearing age, inform them of the 
risks of alcohol consumption during pregnancy, and advise them not to drink alcoholic 
beverages during pregnancy [12]. Per these guidelines, pregnant women and women who 
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consider becoming pregnant or may become pregnant should abstain from alcohol. Because 
approximately half of pregnancies are unplanned and women often do not recognize 
pregnancy until 4-6 weeks gestation, sexually active women of childbearing age who do not 
consistently use effective contraception and combine the possibility of pregnancy with risky 
drinking are at high risk for an alcohol-exposed pregnancy. Although the specific amount of 
alcohol that can cause an FASD is unknown, the at-risk drinking threshold has been 
established as > 7 standard drinks per week or > 3 standard drinks on a day [13] or ≥ 4 
standard drinks on a single occasion (i.e., binge drinking that results in a 0.08% gram or 
higher blood alcohol concentration) [14].
The Substance Abuse and Mental Health Services Administration recommends Screening, 
Brief Intervention, and Referral to Treatment (SBIRT) as part of routine health care in 
numerous settings, including primary care, emergency departments, trauma centers, and 
other community care centers [15]. The American Academy of Obstetricians and 
Gynecologists (ACOG) guidelines recommend screening for problematic drinking for all 
women seeking obstetric–gynecologic care annually and within the first trimester of 
pregnancy, with early intervention strategies encouraging healthy behaviors and appropriate 
referrals to a substance abuse professional when indicated [16, 17]. ACOG recommends the 
T-ACE (Tolerance, Annoyance, Cut Down, Eye-Opener) and CAGE (Cut Back, Annoyed, 
Guilty, Eye-Opener) screening tools [17]. The American Academy of Family Physicians 
recommends universal alcohol use screening for all women of childbearing age and for 
mothers of patients with clinical features worrisome for FASDs (facial dysmorphia, growth 
deficiencies, central nervous system impairment) [18, 19]. The FASD Advisory Workgroup 
in Canada recognizes that there is no general consensus for screening for alcohol use in 
women of childbearing age, and issues recommendations to improve screening and 
recording processes of alcohol use among women of child-bearing age [20]. The 
recommendations include a three-level PAE identification model: 1) practice-based 
approaches, such as motivational interviewing and supportive dialogue, implemented by 
health care providers when talking to women about alcohol use, 2) structured questionnaires, 
such as CAGE or T-ACE, and 3) biological tests to confirm the presence of alcohol or a 
drug, the level of exposure, and the presence of multiple drugs.
As part of routine adolescent care, the American Academy of Pediatrics Bright Futures 
[21-23] recommends a universal substance use screening, brief intervention, and referral to 
treatment protocol, using CRAFFT, a developmentally appropriate screening tool for 
alcohol and drug use [21, 22]. However, the framework for screening for parental substance 
use, including maternal alcohol use during pregnancy in pediatric practice is limited. The 
parent is not the pediatrician's patient, so there is no financial reimbursement for parental 
screening or a brief intervention. Furthermore, if a clinician encounters concerns for 
problematic substance use, referring the parent to appropriate treatment resources becomes a 
challenge. Even in the setting of adolescent pregnancy, where both the mother and the child 
are pediatric patients, there are no clear recommendations for PAE screening, prevention, 
and treatment with appropriate resources.
A review of the professional guidelines indicates some similarities; however, there is a lack 
of consistency in methods and recording results in medical records and no consensus 
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regarding whether all pediatric patients should be screened for PAE [18, 19]. In order to 
identify FASDs in children and provide effective treatment, pediatric clinicians ultimately 
bear the responsibility for detecting PAE and, therefore, are tasked with the challenge of 
screening the mothers of their patients. Although primary care and obstetric clinicians have 
been tasked with screening and brief interventions to reduce at-risk drinking and prevent 
FASDs, the identification of maternal alcohol consumption is a relatively new task for 
pediatric clinicians. There is uncertainty about the actions that a pediatrician is expected to 
implement if a mother reports alcohol or drug use and about whether the pediatrician is 
expected to conduct a brief intervention or refer the parent for treatment if indicated. 
Understanding the current practices of pediatric clinicians is crucial to facing these 
challenges and improving identification of PAE.
Prenatal alcohol screening practices among pediatric and other clinicians
Studies indicated that many pediatricians do not routinely screen their patients for PAE. 
Vagnerelli et al. [24] reported that 59% of Italian neonatologists, 78.4% of Italian 
pediatricians, and 60% of Spanish pediatricians endorsed always asking new mothers about 
ethanol consumption during pregnancy. Over 90% of all clinicians who reported PAE 
screening among new mothers used general questions, with less than 10% reporting use of 
standardized screening tools [24]. Nanson et al. [25] obtained information about screening 
practices among Canadian pediatricians and family and general physicians (FP/GP); 
pediatricians were less likely to screen mothers about their alcohol use during pregnancy 
than were FP/GP (58.3% vs 77.4%). An earlier survey asked a small sample of Texas 
practitioners what percentage of colleagues they believed screened for FAS, and the mean 
response was 30%; however, this study did not specifically examine the practitioners’ 
screening practices [26].
Other medical providers, including obstetricians and FP/GP, often routinely conduct PAE 
screening with pregnant and non-pregnant women of childbearing age, but utilization of 
standard screening tools is limited [26]. A survey of Canadian family physicians revealed 
that while 75% reported asking pregnant patients about alcohol use, they were unaware of 
current screening methods to accurately gauge alcohol use among women [27]. Another 
Canadian study found that 94% of family physicians, midwives, and obstetricians reported 
asking their pregnant patients about alcohol use; however, only 74% of family physicians, 
45% of obstetricians, and 20% of midwives utilized a standard screening tool [28]. 
According to Tough [28], less than 50% of Canadian healthcare providers caring for women 
in the preconception period reported frequently discussing smoking, alcohol use, or 
addiction history. Arnold et al. [29] found that only 38% of medical students and residents at 
an U.S. university reported always screening their pregnant patients for alcohol use, 
suggesting that there is a need to educate practicing clinicians and trainees about the 
importance of PAE screening. In general, few articles reported the specific methods used to 
screen for PAE.
Barriers to screening for PAE
Pediatric clinicians face many barriers to accurate detection of PAE, given the social stigma, 
legal implications, and other factors. Women under-report alcohol consumption because of 
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embarrassment, fear, or beliefs that small amounts of alcohol are inconsequential [30, 31]. 
Coles [30] noted that alcohol use is reported less frequently than other drug use in medical 
records. Many adopted and foster care children are at high risk of having had PAE, yet they 
are often no longer in the care of their biological mother. Clinicians must thus rely upon 
secondary reports of maternal alcohol use during pregnancy. Because many children have 
come into the care of other biological relatives or the foster care system, exposure 
information must often be obtained from medical/social service records or by hearsay. 
Studies have shown that information yielded in this manner is often less accurate than direct 
maternal self-report, contributing to the under-diagnosis of FASDs [30]. When pediatric 
clinicians have contact with their patients’ biological mothers, many find it difficult and feel 
uncomfortable asking parents about their alcohol use, and if the history is not obtained in a 
sensitive manner, parents may feel blamed for wrong-doing. Mothers may not reveal their 
alcohol use during pregnancy because of guilt or fear of legal actions that could result in 
losing their job, children, or relationships [31].
Clinicians may be reluctant to document PAE due to concerns with mandatory reporting of 
child maltreatment. ACOG states, “Seeking obstetric-gynecologic care should not expose a 
woman to criminal or civil penalties or the loss of custody of her children” [16, 17]. 
Discussing the role of obstetrician-gynecologists in substance abuse reporting and 
pregnancy, ACOG has expressed concerns that the threat of prosecution is an ineffective 
strategy in reducing the incidence of alcohol or drug abuse; it may deter women from 
seeking prenatal care which would be contrary to the child and maternal welfare [16].
The new Child Abuse Prevention and Treatment Act (CAPTA) [32] does not require 
clinicians to report maternal alcohol use or PAE to Child Protective Services (CPS). 
However, if a child is diagnosed with FAS/FASDs, clinicians are required to make a referral 
to CPS so that safe care plans and services are initiated. Additional laws regarding FASDs 
may differ based on the state in which the clinician practices. These new laws and 
procedures can improve services for children diagnosed with FASDs but could also increase 
challenges in obtaining accurate self-reports about alcohol use during pregnancy. When 
children are older at their first referral, diagnosis relies on the maternal recall of alcohol use 
after a period of years by a woman who may not remember well or may have some 
motivation, conscious or unconscious, to downplay the extent of use [30]. Pediatric 
clinicians should be aware of the reporting guidelines for reporting FASDs to child welfare 
and reporting guidelines related to maternal alcohol use within their states and include 
during their regular discussion of consent to evaluation/treatment and disclosure with the 
family. Health care professionals may be encouraged to work with state legislators to ensure 
that legislation support education and services to women instead of punishing pregnant 
women for substance use.
In addition, if a mother reveals alcohol misuse, a pediatrician may feel uncomfortable 
because of limited skills, time, or resources necessary to adequately respond to the reported 
problem. Many pediatric clinicians lack screening and brief intervention (SBI) skills and 
knowledge of community resources on alcohol misuse. Since pediatricians are already 
tasked with providing SBI for substance abuse in adolescent patients with high risk for 
pregnancy [21, 22, 23, 33], they may be well-poised to assist in providing SBI to mothers of 
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their patients who report at-risk drinking. However, there are barriers to reimbursement for a 
brief intervention for a parent, a lack of skills to conduct SBI, and no formal pediatric 
guidelines for such services. Pediatricians need guidelines, training, and resources for 
improving detection of PAE in their patients and should be provided with specific 
instructions if they are to help prevent future PAE and FASDs.
Several studies have surveyed clinicians to inquire about their perception of barriers to 
eliciting a self-report of PAE. A survey of U.S. obstetricians identified several barriers, 
including physician bias due to own alcohol misuse, lack of training, poor awareness of the 
problem and its effects, denial that FAS occurs in private practice, time limitations, lack of 
interest, fear of offending the patient, and fear that patients will lie [34]. Another study 
reported that family physicians and obstetricians were 60% more likely to identify time 
constraints as a barrier to discussing alcohol use during pregnancy with women than were 
midwives, and almost half of all providers felt that existing information available for 
discussing PAE not in a useful form for clients [28]. An in-depth focus group of prenatal 
care providers in San Francisco indicated that practice setting strongly influenced providers’ 
screening and counseling of pregnant women about tobacco, alcohol, and illicit drug use. 
Providers with larger settings, like county hospitals and the Health Maintenance 
Organization (HMO), reported more resources, compared with private practitioners. HMO 
providers were also more likely to report using standardized questionnaires and toxicology 
screening in pregnancy. In contrast, private practices appeared to offer greater continuity of 
care and patient-provider relationships [35]. Clinicians have also reported the lack of 
training and confidence about FAS/FASDs as barriers to identification and diagnosis. In a 
study of Toronto family physicians, 49% reported little confidence in their ability to 
diagnose FAS; 81% felt their training was inadequate [27]. Italian and Spanish 
neonatologists and pediatricians also had low confidence in their ability to diagnose FAS 
and FASDs, with over 50% feeling that they needed more information regarding FAS/FASD 
identification in newborns and children [24].
Biomarkers in detecting PAE
Biological tests utilize maternal or child specimens, such as urine, blood, hair, meconium, 
and umbilical cord samples [36]. Biomarkers of PAE include direct ethanol metabolites/
conjugation products, such as fatty acid ethyl esters (FAEEs), phosphatidylethanol (PEth), 
ethyl glucuronide (EtG), and ethyl sulfate (EtS), and indirect ethanol-induced protein 
alterations, such as gamma glutamyltranspeptidase (GGT) [37, 38•, 39-41]. Several studies 
indicate that biomarkers reveal higher prevalence of alcohol use during pregnancy than do 
maternal self-reports. A study indicated a fivefold increase in detection of PAE from a 
meconium FAEE test compared with traditional self-reports in a population-based sample in 
Canada [42]. A recent review reported PAE prevalence 4.3 times higher when testing 
meconium than relying on maternal self-reports [43]. These approaches are promising for 
detecting PAE. However, there are several drawbacks: (1) the methods are costly and may 
be invasive, (2) nearly two-thirds of problem drinkers do not have elevated test values, (3) 
scores may be elevated due to other factors, such as maternal diabetes or diet, and (4) the 
methods do not indicate either the amount or the time period of drinking [41]. Traditionally 
utilized biomarkers, such as urine and blood testing, only provide information about 
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drinking within the last several hours. Other biomarkers, such as meconium or hair testing, 
provide information about PAE during the last two trimesters of pregnancy. However, these 
methods are expensive, detect heavier alcohol use, and may be less reliable in detecting 
moderate or social drinking. In addition, no currently known biomarker can detect exposure 
during the first trimester.
When a pediatric clinician orders biomarkers on an infant, results may reveal information 
about the mother, who is not their patient, which raises an ethical concern. Universal 
biomarker screening raises additional ethical questions. Implementing informed consent to 
patients about testing and providing biomarker screening only to those who consented 
reduces the benefits of testing, since patients who consumed alcohol are more likely to 
refuse testing [44]. However, testing without patient consent would violate the patient's right 
for autonomy. An additional consideration is that if biomarker screenings were to be 
routinely used, intervention resources would need to be available [36]. Identification of PAE 
in older children is even more challenging, as no current laboratory test can detect and 
quantify PAE in older children.
Some hospitals have implemented targeted biomarker screening and may have established 
algorithms to determine risk for PAE (e.g., specific concerns due to lack of prenatal care, 
premature birth, low birth weight, or mother's intoxication at admission; personal 
communication with Raja Nandyal, M.D., and Vadim Ivanov, M.D., neonatologists at 
University of Oklahoma Children's Hospital, February 2015). However, there is no 
commonly accepted algorithm or procedure to record biomarker results in maternal medical 
charts, and transferring the information to the child's health records had been inconsistent in 
the U.S. and Canada [20].
Although biomarker screening could offer advantages over maternal self-reports, research is 
needed to further validate biomarkers and improve PAE detection [45]. Given these 
limitations, maternal self-report remains the most common method to assess for PAE in 
clinical practice.
Strategies for improving identification of PAE through maternal self-report
Self-reports about alcohol consumption have been demonstrated to reliably reflect women's 
alcohol consumption. Babor et al. [46] indicated that, in clinical trials of research volunteers, 
self-report measurements are accurate. Biomarker tests and collateral informant reports do 
not add sufficient data to warrant their routine use. However, most published data regarding 
the reliability of self-reports were obtained from volunteers who provided anonymous or 
confidential information in research studies. A physician asking about alcohol use as part of 
a clinic appointment in which information is not anonymous and is likely to be included in 
the patient's medical record makes self-reports more likely to be affected by a social 
desirability bias. A recent study reported that in-depth research interviews revealed more 
alcohol use among pregnant women than was recorded during routine clinical care 
appointments with these women [47].
Several approaches to improve the accuracy of self-reports of alcohol consumption and PAE 
identification have been identified. Physicians can improve self-report accuracy by asking 
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questions in a sensitive and nonjudgmental manner [33-36] and when embedding questions 
about alcohol use in the routine prenatal history that includes nutrition, exercise, and 
avoidance of environmental toxins, such as nicotine/second-hand smoke. In order to increase 
accurate and truthful reporting, the woman must be alcohol- and drug- free when 
interviewed, and the interviewer must use simple language and provide word questions 
clearly [48]. Asking a woman about her drinking patterns before she became pregnant is 
another strategy that could elicit more accurate estimates of first-trimester drinking and 
alcohol use later during pregnancy [49]. Robles et al. [50] found that self-reported alcohol 
consumption is moderately reliable over 3-month and 5-month time periods, and longer 
timeframes have been documented to improve sensitivity of self-reports in women of 
childbearing age [51]. A summary of PAE screening recommendations for pediatric practice 
is included in Table 1. Figure 2 provides a suggested algorithm for implementing PAE 
screening and appropriate action plans based upon risks identified within a pediatric 
practice.
Screening instruments to identify alcohol use during pregnancy
A number of screening measures have been implemented for screening for at-risk drinking 
in different settings. Two of the instruments have been designed and validated specifically to 
detect the risk for alcohol use during pregnancies in women, TWEAK (Tolerance, Worried, 
Eye-opener, Amnesia, Kut down) and T-ACE [52-54]. These measures have been tested in 
diverse obstetric samples and demonstrated good performance in PAE identification [52, 
55-57]. In addition, the AUDIT-C (Alcohol Use Disorders Identification Test alcohol 
consumption questions) has demonstrated sensitivity in identification of prenatal alcohol use 
among women [58]. Most women who consume alcohol during pregnancy do not meet 
criteria for alcohol use disorders and may not be identified with commonly used 
instruments, such as the standard AUDIT (Alcohol Use Disorders Identification Test) [59]. 
For example, the CAGE questionnaire and SMAST (Short Michigan Alcoholism Screening 
Test) were designed to identify hazardous and harmful drinking and alcohol dependency and 
were tested in specific populations (e.g., heavy-drinkers, males) [60]. These instruments do 
not accurately identify drinking among women [15, 16, 58]. T-ACE and TWEAK, simple 
screening instruments designed for identifying women who consume alcohol during 
pregnancy, are particularly valuable and detecting the risk for PAE.
Single question to identify alcohol use during pregnancy
Even brief instruments consisting of a few questions may be difficult to implement in a busy 
pediatric practice. Recent studies indicate that a single-question can be used for screening. 
The National Institute on Alcohol Abuse and Alcoholism recommended the Single “Binge” 
Drinking Question (SBDQ) (“How often did you have ≥ 4 drinks on one occasion?”) to 
screen people whose drinking puts them at risk of an alcohol use disorder [13]. Recent 
studies found that the SBDQ accurately identified patients with at-risk drinking in primary 
care [61] and also identified women whose drinking placed them at risk of PAE [62-64]. 
These findings support the use of SBDQ to identify prenatal alcohol use. However, the 
studies were conducted in research settings, and additional research is needed to evaluate the 
performance of the measure in pediatric care settings. It is reasonable, though, to conclude 
that the SBDQ and screening instruments, including T-ACE and TWEAK, are feasible and 
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effective for PAE identification and can be recommended for implementation in pediatric 
care settings.
Conclusions
Screening women for at-risk drinking and high risk for alcohol-exposed pregnancies has 
been recommended for primary care, and is widely accepted as a part of routine care by 
many practitioners. Recent findings regarding the clinical features and prevalence of FASDs 
and new DSM 5 guidelines for diagnosing ND-PAE highlight the importance of improving 
PAE identification in pediatric settings. Thus, pediatric clinicians are tasked with eliciting 
accurate maternal self-reports of alcohol use during pregnancy. Since women are more 
likely to provide accurate reports of prenatal alcohol use retrospectively, pediatric clinicians 
should be reassured that they are in the best position to engage in this discussion and can 
prompt accurate information about PAE.
Although challenges in PAE identification have been reported, a significant body of research 
and clinical guidelines support pediatric clinicians in identification of PAE. Currently, 
maternal self-reports about alcohol use are a more practical method of PAE detection than 
biological methods. Several self-report methods, including the SBDQ, have shown validity 
[52, 55, 63-66]. These approaches need further evaluation in clinical settings to determine 
their accuracy when implemented by pediatric professionals. Studies have indicated that 
many clinicians feel they lack the confidence, skills, and time to effectively screen for PAE, 
and that they need training in effective screening methods that require minimal time [24, 27, 
34]. However, few studies have examined the general frequency and methods of PAE 
screening practices used by pediatricians. Additional measures, such as screening by nurses 
and other health care professionals, incorporating screening tools in electronic medical 
records, and utilization of tablets/electronic system screening, can be utilized in pediatric 
offices. By improving recognition of PAE via accurate maternal self-reports, pediatric 
clinicians can improve early identification of FASDs, ensure services and early interventions 
for children with FASDs to prevent secondary disabilities, and potentially contribute to 
prevention of PAE in future pregnancies.
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Standard-sized drink equivalents. [67](With permission from: National Institute on Alcohol 
Abuse and Alcoholism. A Pocket Guide for Alcohol Screening and Brief Intervention. 2005. 
Rockville, MD: National Institutes of Health, 2005.) Available at http://pubs.niaaa.nih.gov/
publications/Practitioner/PocketGuide/pocket_guide.htm. Produced by the American 
College of Gynecologists and Obstetricians [ACOG] .
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Suggested algorithms for assessing prenatal alcohol exposure: action plan. aPAE: prenatal 
alcohol exposure; bND-PAE: neurobehavioral disorder associated with prenatal alcohol 
exposure; cSBI: screening and brief intervention/referral to treatment. (Data adapted with 
permission from: Balachova T. Screening for prenatal alcohol exposure. Alcohol Related 
Neurodevelopmental Disabilities and Prenatal Alcohol Exposure Workgroup Meeting, 
American Academy of Pediatrics, Elk Grove Village, February 24, 2014) [68].
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Table 1
Prenatal alcohol exposure screening recommendations for pediatric settings (SUPER)
Support • Provide empathy and support in a non-judgemental manner.
Universally Screen with 
Evidence-based screening 
tool
• Universally screen for PAE
a
 prenatally and in the newborn period; selectively screen throughout childhood.
• Embed alcohol screening in routine prenatal questioning regarding other health behaviors prior and during 
pregnancy: nutrition, vitamin use, physical exercise, and the avoidance of environmental toxins, such as nicotine 
and second-hand smoke.
• To “normalize” the questioning about alcohol use, start with a general statement, like “I ask all my patients' 
parents standard health questions to understand factors that may affect the health of their child.”
• Perform frequent developmental screening if PAE is identified.
Pre-pregnancy and 
Pregnancy alcohol use
• To approach the topic of alcohol and quickly determine whether prenatal exposure occurred, the following set of 
questions is recommended:
    1. “In the 3 months before you knew you were pregnant, how many times did you have 4 or more alcohol 
drinks in a day?”
    2. “During your pregnancy, how many times did you have any alcohol?”
• If a positive response is given to either question above, it is recommended that the clinician follow up to 
determine the level of PAE by asking:
    3. “During your pregnancy, on average, how many days per week did you have any alcohol?”
    4. “During your pregnancy, on a typical day when you had an alcoholic beverage, how many drinks did you 
have?”
    5. “During your pregnancy, what was the maximum number of drinks that you had in a day?”
Educate • Educate women about the risks of alcohol use during pregnancy and advise them to avoid alcohol consumption 
while pregnant or when conception is possible.
Record, Report, Refer • Any affirmative answer to above questions indicates maternal at-risk drinking and minimal or higher PAE.
• The presence of PAE (pre-pregnancy binge drinking, during pregnancy any alcohol use) and, if possible, the 
PAE level (during pregnancy the number of drinking days/week, average number of drinks/day, and the maximum 
number of drinks/day) must be documented in the child's medical record. Documentation of PAE in child's 
medical records is important for diagnosing ND-PAE
b
 or other FASD condtions at the time of the evaluation or 
later if disorders become evident later in life.
• Guidelines should be followed for the child with PAE, including a referral to a developmental specialist.
• Consider legal reporting guidelines for reporting FASDs to Child Welfare; include during regular discussion of 
treatment consent and disclosure with the family.
• If maternal at-risk drinking and PAE is identified, a brief intervention/referral for the mother is indicated to 
prevent PAE in a future pregnancy and reduce her own health risk.
a
PAE: prenatal alcohol exposure
b
ND-PAE: neurobehavioral disorder associated with prenatal alcohol exposure (Data adapted with permission from: Balachova T. Screening for 
prenatal alcohol exposure. Alcohol Related Neurodevelopmental Disabilities and Prenatal Alcohol Exposure Workgroup Meeting, American 
Academy of Pediatrics, Elk Grove Village, February 24, 2014) [68].
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